June 18, 2024

Dear Rett Patient Advocacy Leaders,

Today, Taysha shared interim clinical data from the REVEAL Adolescent & Adult and the REVEAL Pediatric Study which are both evaluating TSHA-102, an investigational gene therapy for Rett syndrome. These data will be presented at the 2024 International Rett Syndrome Foundation (IRSF) Rett Syndrome Scientific Meeting June 18-19, 2024, in Colorado. Please find a summary below as well as answers to frequently asked questions.

What are the interim findings from cohort one (low dose) in the REVEAL Studies?
It is important to note that we cannot make any conclusions on interim findings of a clinical trial until all enrolled subjects are dosed and evaluated for the duration of the study, and once all the data have been collected and analyzed. Making conclusions about interim data may not accurately predict the full risk/benefit profile of an investigational product.

- **Interim data collected in the REVEAL Adolescent & Adult Study (females age 12+) from the two participants in cohort one (low dose) showed:**
    - There have been no serious adverse events (SAEs) related to TSHA-102 as of 52 weeks following administration (participant one) and as of 36 weeks following administration (participant two).
    - Longer-term data from both adult patients showed sustained and new improvement across multiple clinician and caregiver-assessed efficacy measures (CGI-I, PGI-I, R-MBA, seizure diaries) at the 52-week (participant one) and 25-week (participant two) time points following administration of TSHA-102.
    - In addition, clinical observations reported by the Principal Investigator showed sustained and new improvements in motor skills, communication/socialization, autonomic function and seizures.

- **Interim data collected in the REVEAL Pediatric Study (females 5-8 years old) from the two participants in cohort one (low dose) showed:**
    - There have been no SAEs related to TSHA-102 as of 22 weeks following administration (participant one) and as of 11 weeks following administration (participant two).
        - One participant experienced two SAEs that were not deemed treatment-related (both were related to underlying disease and one was also attributed to immunosuppression) and have resolved.
    - Initial data from the first two pediatric patients showed improvements across multiple clinician and caregiver-assessed efficacy measures (CGI-I, PGI-I, R-MBA, seizure diaries) at the 12-week (participant one) and 8-week (participant two) time points following administration of TSHA-102.
    - In addition, clinical observations reported by the Principal Investigator showed improvements in motor skills, communication/socialization, autonomic function and seizures.

When will additional data from the REVEAL Phase 1/2 Studies be shared?

- Taysha plans to share initial safety and efficacy data from cohort two (high dose) of the REVEAL Adolescent & Adult and the REVEAL Pediatric Study in the second half of 2024.

What are the goals of the REVEAL Phase 1/2 Studies?

- The REVEAL Adolescent & Adult Study (ages 12+) and the REVEAL Pediatric Study (ages 5-8) are Phase 1/2 studies designed to evaluate whether TSHA-102 is safe, whether it is tolerable, and whether there may be beneficial effects in females with Rett syndrome. The studies are also designed to evaluate two dose levels to determine the highest tolerable dose of TSHA-102.

How many participants have received TSHA-102 across the two REVEAL Studies?

- In the REVEAL Adolescent & Adult Study (ages 12+), two participants have received the low dose of TSHA-102. Today, Taysha shared that a third participant in this study recently received the high dose.
- In the REVEAL Pediatric Study (ages 5-8), two participants have received the low dose of TSHA-102. The Independent Data Monitoring Committee (IDMC) approved Taysha's request to advance to cohort two (high dose) in the REVEAL Pediatric Study. Dosing is expected in Q3 2024 following IDMC review of initial safety data from the first high dose patient in the REVEAL Adolescent & Adult Study.

Where is the REVEAL Adolescent & Adult Study (females age 12+) being conducted? Who can families contact for more information?

- The study is being conducted in Canada and Taysha recently announced the expansion of the ongoing trial into the U.S.
- Families can contact one of the participating clinical trial sites whose contact information is available at https://clinicaltrials.gov/study/NCT05606614. Additional trial sites will be posted as they become active.

Where is the REVEAL Pediatric Study (females 5-8 years old) being conducted? Who can families contact for more information?

- The study is being conducted in the U.S. and Taysha announced authorization from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) to expand the ongoing trial into the U.K. Additional information and clinical trial sites will be posted at https://clinicaltrials.gov/study/NCT06152237 once available.
- Families can contact one of the participating clinical trial sites whose contact information is available at https://clinicaltrials.gov/study/NCT06152237. Additional trial sites will be posted as they become active.

We would like to thank the entire Rett community and the Rett patient advocacy groups for your continued partnership. We would also like to acknowledge the individuals and families who choose to participate in research to help better understand the potential of gene therapy for Rett syndrome.

We look forward to sharing more information as it is publicly available.

Sincerely,
The Taysha Patient Affairs Team
patientaffairs@tayshagtx.com